Roche’s potential Alzheimer’s drug crenezumab fails in Phase 2 clinical trial
In the study, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Jun 22
In the study, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation…
16 Jun 22
Under the collaboration, the Abu Dhabi health regulator and Sanofi will develop data generation and population research projects…
16 Jun 22
The rolling review is initially based on chemistry, manufacturing, and controls (CMC) data, which the vaccine manufacturers shared…
15 Jun 22
With the collaboration with Agilent, Merck will extend its real-time monitoring and automated process control of critical process…
15 Jun 22
The US antitrust watchdog has issued a letter to the company that said the FTC was investigating whether…
14 Jun 22
Albrioza, also known as AMX0035, is an oral fixed-dose combination therapy that works to reduce neuronal cell death…
14 Jun 22
The FDA approval is supported by Lilly’s BRAVE-AA1 and BRAVE-AA2 clinical trials, which evaluated the efficacy and safety…
13 Jun 22
The company’s investigational RSV vaccine candidate RSVPreF3 OA has showed statistically significant and clinically meaningful efficacy in adults…
13 Jun 22
The US regulator required a patient notification about suicidal behaviour, where it has previously approved an expanded its…
10 Jun 22
The acquisition will provide Pfizer with ReViral’s portfolio of therapeutic candidates, including sisunatovir, along with another lead candidate,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates